1Czaja MJ.Pioglitazone:more than just an insulin sensitizer.Hepatology,2009,49:1427-1430.
2Catherine P,Jean G.Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance:lessons from genetically engineered mice.J Clin Invest,2008,118(3):829-838.
3Promrat K,Lutchman G,Uwaifo GL,et al.A pilot study of pioglitazone treatment for nonalcoholic steatohepatits.Hepatology,2004,39(1):188.
4Neuschwander-Tetri BA,Brunt EM,Wehmeier KR,et al.Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.Hepatology,2003,38(4):1008-1017.
5Sanyal AJ,Mofrad PS,Contos MI,et al.A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.Clin Gastreenterol Hepatol,2004,2 (12)(1)107.
6Chao HW,Ching HL,Sung CL,et al.Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease.J Formos Med Assoc,2006,105(9):743-752.
7Aithal GP,Thomas JA,Kaye PV,et al.Randomized,placebocontrolled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.Gastroenterology,2008,135 (4):1176-84.
8Ratziu V,Giral P,Jacqueminet S,Charlotte F,et,al.Rosiglitazone for nonalcoholic steatohepatitis:one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.Gastroenterology,2008,135(1):100-10.
9Belfort R,Harrison SA,Brown K,et al.A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med,2006,355(22):2297 -2307.
10Lutchman G,Promrat K,Kleiner DE,et al.Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis:relationship to histological improvement.Clin Gastroenterol Hepatol,2006,4(8):1048-1052.
2Wolffrenbuttel BHR,Gomist R,Squatrito S,et al.Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients.Diabetic Med,2000,17:40-47.
3Pradhan A D,Manson J E,Nader R,et al.C-reactive protein,interleukin-6,and risk of developing type 2 diabetes mellitus.JAMA,2001,286:327-334.
4Pickup JC,Crook MA.Is type Ⅱ diabetes mellitus a disease of innate immune system? Diabetologia,1998,41:1241-1248.
5Grigsby RJ,Dobrowsky RT.Inhibition of ceramide productionreverses TNF-induced insulin resistance.Biochem Biophys Res Commun,2001,287:1121 1124.
7Day CP,James OF.Steatohepatitis:a tale of two "hits".J.Gastroenterology,1998,114:842-845.
8Willner IR,Waters B,Patil SR,et al.Ninety patients with nonalcoholic steatohepatitis:insulin resistance,familial tendency,and severity of disease.Am J Gastroenterol,2001,96:2957-2961.
9Katoh SH,Hata S,Matsushima M.Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy-a randomized controlled trial.Metabolism,2001,50:414-417.
10Caldwell SH,Hespenheide EE,Redick JA,et al.A pilot study of a thiazolidinedione,troglitazone in nonalcoholic steatohepatitis.Am J Gastroenterd,2001,96:519-525.
